>중동 및 아프리카 IgA 신증 시장, 질병 유형(1차 IgA 신증 및 2차 IgA 신증), 증상(혈뇨, 단백뇨, 부종 및 기타), 유형(진단 및 치료), 인구 유형(소아과 및 성인), 투여 경로(경구, 비경구 및 기타), 최종 사용자(병원, 진료소, 가정 의료 및 기타), 유통 채널(직접 입찰, 병원 약국, 소매 약국, 온라인 약국 및 기타), 국가(사우디 아라비아, 남아프리카, UAE, 이스라엘, 쿠웨이트, 이집트 및 중동 및 아프리카의 나머지 지역) 산업 동향 및 2028년까지의 예측
시장 분석 및 통찰력: 중동 및 아프리카 IgA 신증 시장
IgA 신증 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 18.6%의 CAGR로 성장하고 있으며 2028년까지 3,269만 달러에 도달할 것으로 예상한다고 분석합니다. IgA 신증에 대한 약물 발견 증가는 예측 기간 동안 시장 수요를 견인하는 주요 원동력입니다. IgA 신증 장애의 증가는 질병 부담을 증가시켜 진단 및 치료 제품에 대한 수요를 증가시키고, 따라서 IgA 신증 시장 성장을 견인하는 역할을 합니다.
IgA 신병증은 버거병이라고도 하며, 신장에 IgA 침전물이 쌓여 염증을 일으키고 신장 조직을 손상시키는 신장 질환 입니다. IgA와 같은 항체는 면역 체계가 박테리아와 바이러스를 포함한 이물질로부터 신체를 보호하기 위해 생성하는 단백질입니다. 이 질환의 합병증은 ESKD로, 치료를 위해 투석이 필요합니다.
증가하는 IgA 신증 타겟 파이프라인 약물은 잠재적 후보가 IgA 신증 치료의 효능을 보여줄 수 있게 하므로 IgA 신증 시장의 원동력으로 작용합니다. IgA 신증 치료 비용은 환불이 없는 경우 환자의 주머니 부담을 증가시키므로 IgA 신증 시장 성장에 제약으로 작용합니다. 약물 개발을 위한 시장 참여자의 협력은 시장에서의 입지와 혁신을 증가시켜 IgA 신증 시장 성장의 기회로 작용합니다. IgA 신증 치료와 관련된 부작용과 면역 억제제 시장에 미치는 COVID-19의 영향은 IgA 신증 시장 성장에 도전으로 작용합니다.
The IgA nephropathy market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the IgA nephropathy market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
IgA Nephropathy Market Scope and Market Size
The IgA nephropathy market is segmented on the basis of the disease type, symptoms, type, population type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the IgA nephropathy market is segmented into primary IgA nephropathy and secondary IgA nephropathy. In 2021, primary IgA nephropathy segment is expected to dominate the market because the incidence of primary IgA nephropathy is more and can be diagnosed by blood or urine test easily.
- On the basis of symptoms, the IgA nephropathy market is segmented into hematuria, proteinuria, edema and others. In 2021, hematuria segment is expected to dominate the market as it is the most common and frequently used parameter for clinical examination and is detected by the amount of blood in the urine showing the occurrence of disease in the kidney.
- On the basis of type, the IgA nephropathy market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market due to the fact that prior given the treatment, the proper detection and tracing of the IgA nephropathy is necessary which is possible only through the primary detection such as blood and urine test and confirmatory detection by kidney biopsy which are the major factor of this segment to dominate.
- On the basis of population type, the IgA nephropathy market is segmented into pediatrics and adults. In 2021, the adults segment is expected to show the significant growth because the studies showed the connection of this disease with ageing.
- On the basis of route of administration, the IgA nephropathy market is segmented into oral, parenteral and others. In 2021, the oral segment is expected to dominate the market due to the wide variety of oral product portfolio available in the interstate commerce by the market which increases the market of this segment.
- On the basis of end user, the IgA nephropathy market is segmented into hospitals, clinics, home healthcare and others. In 2021, hospitals segment is expected to dominate the market due to its strong financial structure.
- 유통 채널을 기준으로 IgA 신증 시장은 직접 입찰, 병원 약국, 소매 약국, 온라인 약국 등으로 세분화됩니다. 2021년 직접 입찰 부문은 매출 성장을 가속화하고 세금 혜택을 제공하여 직접 입찰 부문이 지난 몇 년 동안 번창하고 있으며, 이는 시장의 추가 성장을 긍정적으로 보여줍니다.
중동 및 아프리카 IgA 신증 시장 국가 수준 분석
중동 및 아프리카 IgA 신증 시장을 분석하고, 위에 언급된 대로 국가, 질병 유형, 증상, 유형, 인구 유형, 투여 경로, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다.
중동 및 아프리카 IgA 신증 시장 보고서에서 다루는 국가는 사우디아라비아, 남아프리카공화국, UAE, 이스라엘, 쿠웨이트, 이집트, 그리고 나머지 중동 및 아프리카 국가입니다.
중동과 아프리카는 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상되는데, 중동과 아프리카 국가에서 IgA 신증에 대한 수요가 IgA 신증 제품에 대한 수요 증가로 인해 증가하고 있기 때문입니다. 사우디 아라비아는 중동과 아프리카 IgA 신증 시장을 지배할 것으로 예상되는데, 사우디 아라비아는 중동과 아프리카에서 첨단 IgA 신증 제품과 서비스를 활용하는 주요 국가 중 하나이기 때문입니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
제조업체의 전략적 이니셔티브는 IgA 신병증 시장의 플레이어에게 새로운 기회를 창출합니다.
IgA 신증 시장은 또한 모든 국가 성장에 대한 자세한 시장 분석을 제공합니다. 게다가 중동 및 아프리카 지역의 IgA 신증 시장 참여자 간의 IgA 신증 판매, 파트너십, 인수, 유통 계약의 성장에 대한 자세한 데이터를 제공합니다. 이 데이터는 2011년부터 2019년까지의 과거 기간에 대해 제공됩니다.
경쟁 환경 및 IgA 신증 시장 점유율 분석
IgA 신증 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 범위, 응용 분야 우세 및 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 중동 및 아프리카 IgA 신증 시장과 관련된 회사의 초점에만 관련됩니다.
중동 및 아프리카 IgA 신증 시장 보고서에서 다루는 주요 기업으로는 AstraZeneca, Novartis AG, Pfizer Inc., Zydus Cadila, Fresenius Kabi USA(Fresenius SE & Co. KGaA의 자회사), Teva Pharmaceuticals USA, Inc.(Teva Pharmaceutical Industries Ltd.의 자회사), Hikma Pharmaceuticals PLC, LUPIN, Siemens Healthcare GmBH(Siemens Healthineers AG의 자회사), Sun Pharmaceutical Industries Ltd., ARKRAY USA, Inc., Merck Sharp & Dohme Corp.(Merck & Co., Inc.의 자회사), CareDX, Inc., Alembic Pharmaceuticals Limited, Strides Pharma Science Limited, Apotex Inc. 등이 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 여러 회사에서 많은 계약과 협정을 체결하면서 IgA 신증 시장도 활성화되고 있습니다.
예를 들어,
- 2020년 9월, LUPIN은 10세 이상 성인과 어린이의 콜레스테롤을 낮추는 데 사용되는 10mg/ 20mg/ 40mg 및 80mg으로 제공되는 Atorvastatin 칼슘 정제 USP를 출시한다고 발표했습니다. 이 제품 출시는 회사가 더 많은 수익을 올리는 데 도움이 되었습니다.
시장 참여자들의 협력, 합작투자 및 기타 전략은 IgA 신증 시장에서 회사의 인상을 강화하고 있으며, 이는 기업이 IgA 신증 판매 성장을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
4.3 CURRENT STUDIES ON ARCHAEOSOMES
5 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPETITIVE ENVIRONMENT
6 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: REGULATIONS
6.1 THE U.S. REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
6.2 EUROPE REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
6.3 JAPAN REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
7 EPIDEMIOLOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 MIDDLE EAST AND AFRICA RISE IN IGA NEPHROPATHY DISORDER
8.1.2 1.1.2 INCREASING IGA TARGETED PIPELINE DRUGS
8.1.3 INCREASE RESEARCH & DEVELOPMENT INVESTMENT FOR DRUG DISCOVERY
8.1.4 REIMBURSEMENT PROVIDED FOR KIDNEY DISORDERS
8.1.5 1.1.5 UPCOMING AND RECENT APPROVAL FOR IGA NEPHROPATHY TREATMENT
8.2 RESTRAINTS
8.2.1 HIGH COST OF IGA NEPHROPATHY TREATMENT
8.2.2 DELAYED DIAGNOSIS OF IGA DISORDERS
8.2.3 POOR PLANNING OF IGA NEPHROPATHY TREATMENT IN LOW-INCOME COUNTRIES
8.2.4 INABILITY TO STOP PROGRESSION OF IGA NEPHROPATHY BY CURRENT TREATMENT
8.3 OPPORTUNITIES
8.3.1 COLLABORATION OF MARKET PLAYERS FOR DRUG DEVELOPMENT
8.3.2 GOVERNMENT FUNDING FOR RESEARCH PURPOSE
8.3.3 INCREASE TREND FOR NOVEL DIAGNOSIS PROCEDURE
8.4 CHALLENGES
8.4.1 LOW AWARENESS REGARDING KIDNEY DISEASE
8.4.2 SIDE EFFECT IGA NEPHROPATHY TREATMENT DRUGS
9 IMPACT OF COVID 19 ON THE MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT OF DEMAND:
9.3 IMPACT ON SUPPLY CHAIN:
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS:
9.5 CONCLUSION:
10 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 PRIMARY IGA NEPHROPATHY
10.3 SECONDARY IGA NEPHROPATHY
11 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS
11.1 OVERVIEW
11.2 HEMATURIA
11.3 PROTEINURIA
11.4 EDEMA
11.5 OTHERS
12 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY TYPE
12.1 OVERVIEW
12.2 DIAGNOSIS
12.2.1 URINE TEST
12.2.1.1 URINE ALBUMIN-TO-CREATININE RATIO
12.2.1.2 DIPSTICK TEST FOR ALBUMIN AND BLOOD
12.2.2 BLOOD TEST
12.2.3 IOTHALAMATE CLEARANCE TEST
12.2.4 KIDNEY BIOPSY
12.2.5 OTHERS
12.3 TREATMENT
12.3.1 BLOOD PRESSURE LOWERING AGENTS
12.3.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
12.3.1.1.1 LISINOPRIL
12.3.1.1.2 ENALAPRIL
12.3.1.1.3 RAMIPRIL
12.3.1.1.4 BENAZEPRIL
12.3.1.1.5 OTHERS
12.3.1.2 ANGIOTENSIN RECEPTOR BLOCKERS (ARBS)
12.3.1.2.1 LOSARTAN
12.3.1.2.2 VALSARTAN
12.3.1.2.3 IRBESARTAN
12.3.1.2.4 OTHERS
12.3.2 IMMUNOSUPPRESANT
12.3.2.1 CYCLOPHOSPHAMIDE
12.3.2.2 AZATHIOPRINE
12.3.2.3 CORTICOSTEROIDS
12.3.2.3.1 METHYLPREDNISONE
12.3.2.3.2 PREDNISOLONE
12.3.2.3.3 OTHERS
12.3.2.4 OTHERS
12.3.3 DIURETICS
12.3.3.1 FUROSEMIDE
12.3.3.2 TORSEMIDE
12.3.3.3 BUMETANIDE
12.3.3.4 OTHERS
12.3.4 LOWER BLOOD CHOLESTEROL
12.3.4.1 ATROVASTATIN
12.3.4.2 SIMVASTATIN
12.3.4.3 ROSUVASTATIN
12.3.4.4 FLUVASTATIN
12.3.4.5 PRAVASTATIN
12.3.4.6 OTHERS
12.3.5 SUPPLEMENTS
12.3.5.1 OMEGA-3-FATTY ACIDS
12.3.5.2 VITAMIN E
12.3.5.3 OTHERS
12.3.6 OTHERS
13 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY POPULATION TYPE
13.1 OVERVIEW
13.2 ADULTS
13.3 CHILDREN
14 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 TABLETS/PILLS
14.2.2 CAPSULES
14.2.3 OTHERS
14.3 PARENTERAL
14.3.1 INTRAVENOUS
14.3.2 INTRAMUSCULAR
14.3.3 OTHERS
14.4 OTHERS
15 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.4 ONLINE PHARMACY
16.5 DIRECT TENDER
16.6 OTHERS
17 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET BY GEOGRAPHY
17.1 MIDDLE EAST & AFRICA
17.1.1 SAUDI ARABIA
17.1.2 SOUTH AFRICA
17.1.3 ISRAEL
17.1.4 ISRAEL
17.1.5 KUWAIT
17.1.6 EGYPT
17.1.7 REST OF MIDDLE EAST & AFRICA
18 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
19 SWOT
20 COMPANY PROFILES
20.1 VIATRIS INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 TEVA PHARMACEUTICAL USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE FINANCIALS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 LUPIN
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE FINANCIALS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 ACCORD HEALTHCARE
20.4.1 COMPANY SNAPSHOT
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENTS
20.5 ASTRAZENECA
20.5.1 COMPANY SNAPSHOT
20.5.2 RECENT FINANCIALS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENTS
20.6 PFIZER INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE FINANCIALS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 ZYDUS CADILLA
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE FINANCIALS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENTS
20.8 NOVARTIS AG
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE FINANCIALS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENTS
20.9 ALEMBIC PHARMACEUTICALS LIMITED
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.1 STRIDES PHARMA SCIENCE LIMITED
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE FINANCIALS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENTS
20.11 SIEMENS HEALTHCARE GMBH (A SUBSIDIARY OF SIEMENS HEALTHINEERS AG)
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE FINANCIALS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENTS
20.12 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENTS
20.13 HIKMA PHARMACEUTICALS PLC
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE FINANCIALS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENT
20.15 APOTEX INC.
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENTS
20.16 ARKRAY USA, INC.
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
20.17 CALIDITAS THERAPEUTICS AB
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE FINANCIALS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENTS
20.18 CAREDX, INC.
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE FINANCIALS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 OMEROS CORPORATION
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
표 목록
TABLE 1 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA PRIMARY IGA NEPHROPATHY IN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA SECONDARY IGA NEPHROPATHY IN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA HEMATURIA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA PROTEINURIA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA EDEMA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA URINE TEST IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA TREATMENT BY IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA ADUTLS IN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA CHILDREN IN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA HOSPITALS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 SPECIALTY CLINICS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN IGA NEPHROPATHY MARKET, BY REGION, 20190-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOPSITAL PHARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA DIRECT TENDER IN IGA NEPHROPATHY MARKET, BY REGION, 2018-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2018-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 64 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 65 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 66 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 SAUDI ARABIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 SAUDI ARABIA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 SAUDI ARABIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 SAUDI ARABIA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 SAUDI ARABIA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 SAUDI ARABIA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 73 SAUDI ARABIA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 SAUDI ARABIA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 SAUDI ARABIA IGA TREATMENT BY DIURETICS IN NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 SAUDI ARABIA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 84 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 85 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 86 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 SOUTH AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 SOUTH AFRICA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 SOUTH AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 SOUTH AFRICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 SOUTH AFRICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 SOUTH AFRICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 SOUTH AFRICA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 SOUTH AFRICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 SOUTH AFRICA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 SOUTH AFRICA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 97 SOUTH AFRICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 99 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 100 SOUTH AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 101 SOUTH AFRICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 102 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 103 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 104 ISRAEL IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 105 ISRAEL IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 106 ISRAEL IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 ISRAEL DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 ISRAEL DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 ISRAEL TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 ISRAEL TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 ISRAEL TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 ISRAEL TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 ISRAEL TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 ISRAEL TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 ISRAEL TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 ISRAEL TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 117 ISRAEL TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 118 ISRAEL IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 119 ISRAEL IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 ISRAEL ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 121 ISRAEL PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 ISRAEL DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 ISRAELDIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 ISRAEL TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 ISRAEL TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 ISRAEL TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 ISRAEL TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 ISRAEL TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 ISRAEL TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 ISRAEL TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 136 ISRAEL TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 ISRAEL TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 ISRAEL IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 139 ISRAEL IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 140 ISRAEL ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 141 ISRAEL PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 142 ISRAEL IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 143 ISRAEL IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 144 KUWAIT IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 145 KUWAIT IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 146 KUWAIT IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 KUWAIT DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 KUWAITDIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 KUWAIT TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 150 KUWAIT TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 151 KUWAIT TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 KUWAIT TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 KUWAIT TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 KUWAIT TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 KUWAIT TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 KUWAIT TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 KUWAIT TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 KUWAIT IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 159 KUWAIT IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 160 KUWAIT ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 161 KUWAIT PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 162 KUWAIT IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 163 KUWAIT IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 164 EGYPT IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 165 EGYPT IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 166 EGYPT IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 167 EGYPT DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 168 EGYPTDIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 169 EGYPT TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 EGYPT TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 EGYPT TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 EGYPT TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 EGYPT TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 EGYPT TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 EGYPT TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 EGYPT TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 EGYPT TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 EGYPT IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 179 EGYPT IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 180 EGYPT ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 181 EGYPT PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 182 EGYPT IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 183 EGYPT IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 184 REST OF MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: SEGMENTATION
FIGURE 12 MIDDLE EAST AND AFRICA RISE IN IGA NEPHROPATHY DISORDER IS DRIVING THE MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 PRIMARY IGA NEPHROPATHY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET
FIGURE 15 IGA NEPHROPATHY BIOPSIES IN DIFFERENT REGIONS
FIGURE 16 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2020
FIGURE 17 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)
FIGURE 18 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, CAGR (2020-2028)
FIGURE 19 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, 2020
FIGURE 21 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, 2020-2028 (USD MILLION)
FIGURE 22 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, CAGR (2020-2028)
FIGURE 23 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, 2020
FIGURE 25 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 27 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2020
FIGURE 29 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 30 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, CAGR (2020-2028)
FIGURE 31 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 33 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OFADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 35 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER, 2020
FIGURE 37 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER , 2020-2028 (USD MILLION)
FIGURE 38 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER, CAGR (2020-2028)
FIGURE 39 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 42 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 43 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: SNAPSHOT (2020)
FIGURE 45 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY COUNTRY (2020)
FIGURE 46 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 49 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
